Pharmacokinetics of the Proton Pump Inhibitor CDRI-85/92 and its Ester Prodrug, a New H⁺/K⁺-ATPase Inhibitor with Anti-ulcer Activities, after Oral Doses in Rats

Abstract

5-Styryl-4,5-cis-1,3-oxazole-2-one-4-car-boxylic acid (CDRI-85/92) is a new proton pump inhibitor presently in advanced stage of preclinical trials as antiulcer pharmacophore. Since proton pump inhibitors are prodrugs requiring activation in acid environment, an ester prodrug of CDRI-85/92 was also synthesized. In view of the importance, a pharmacokinetic study of CDRI-85/92 and its ester prodrug was conducted after oral doses in rats. Following a 20 mg/kg oral dose of CDRI-85/92, the compound was detectable in the serum samples up to 24 h with a maximum serum concentration (C_max) of 1 838.40 ± 101.16 ng/ml at 1.5 h and an elimination half-life of 4.96 h, whereas, multiple C_max values of CDRI-85/92 were observed with oral doses (equivalent to 20 mg/kg of CDRI-85/92) of the ester prodrug of the compound. All the three C_max values of the compound were lower than that after oral dose of CDRI-85/92. The compound was eliminated slowly from serum with an elimination half-life of 5.14 h. Moreover, the systemic availability of CDRI-85/92 also decreased from 6111 to 3 463 ng · h/ml after the ester prodrug administration. The decrease in systemic availability of CDRI-85/92 could be due to its higher clearance after its ester prodrug administration.

Key words

CDRI-85/92, HPLC, pharmacokinetics, prodrug, rat - Proton pump inhibitor - 5-Styryl-4,5-cis-1,3-oxazole-2-one-4-carboxylic acid

• References

• 1 Sach G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 (Suppl 2) 2-8
• 2 Allegrini A, Nuzzo L, Scaringi AT, Felaco S, Pavone D, Toniato E et al. Bioequivalence study of two capsule formulations of omeprazole in healthy volunteers. Arzneimittelforschung. 2008; 58: 385-8
• 3 Kwon D, Chae JB, Park CW, Kim YS, Leea SM, Eun Ju EJKim et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung. 2001; 51: 204-13
• 4 Sachs G, Shin JM, Briving C, Wallmark B. The pharmacology of the gastric acid pump. The H+, K+ ATPase. Annu Rev Pharmacol Toxicol. 1995; 35: 277-305
• 5 Sanders SW. Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents. Clin Ther. 1996; 18: 2-35
• 6 Dikshit DK, Singh S, Patnaik GK, Srimal RC, Dhawan BN, inventors. Process for the synthesis of 4,5-substituted 2-oxo-4-oxazolidinone carboxylic acid. Indian Patent No. 178841. 1998.
• 7 Dikshit DK, Singh S. 1,2 addition of alpha-amino acids derivatives to conjugated aldehydes: synthesis of 2-substituted serines. Tet Lett. 1988; 29: 3109-13
• 8 Srivastava P, Gupta RC. In situ absorption and protein binding characteristics of CDRI-85/92 an antiulcer pharmacophore. Int J Pharmaceut. 2003; 257: 97-102
• 9 Srivastava P, Sharma P, Lal J, Dikshit DK, Madhusudanan KP, Gupta RC. Metabolism of CDRI-85/92, a new potent antiulcer agent involving cis-trans conversion. Drug Metab Drug Interact. 2004; 20: 57-75
• 10 Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab. 2003; 4: 461-85
• 11 Benet LJ, Zech K. Pharmacokinetics-A relevant factor for the choice of a Drug?. Aliment Pharmacol Ther. 1994; 8: 25-32
• 12 Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ et al. Bioanalytical method validation – A revisit with a decade of progress. Pharm Res. 2000; 17: 1551-7
• 13 Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration: Application of moment analysis. Eur J Clin Pharmacol. 1984; 26: 197-207
• 14 Bergstron RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine pharmacokinetics in normal subjects. Clin Pharmacol Ther. 1981; 30: 404-13
• 15 Piquette-Miller M, Jamali F. Pharmacokinetics and multiple peaking of acebutolol enantiomers in rats. Biopharm Drug Dispos. 1977; 18: 543-56
• 16 Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement JP et al. A double peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double site model for drug absorption. J Pharmacokin Biopharm. 1987; 15: 225-39
• 17 Wang Y, Roy A, Sun L, Lau CE. A double peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos. 1999; 27: 855-9
• 18 Imbimbo BP, Daniotti S, Vidi A, Foschi D, Saporiti F, Ferrante L. Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. J Pharm Sci. 1986; 75: 680-4
• 19 Funaki T, Furuta S, Kaneniwa N. Discontinuous absorption property of Cimetidine. Int J Pharm. 1986; 31: 119-23
• 20 Vanaja M, Dressman JB. Intestinal uptake of cimetidine and ranitidine in rats. Pharm Res. 1994; 11: 1599-604
• 21 Veng-Pedersen P. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci. 1980; 69: 394-8
• 22 Veng-Pedersen P. Pharmacokinetic analysis by linear system approach. I: cimetidine bioavailability and second peak phenomenon. J Pharm Sci. 1981; 70: 32-8
• 23 Levy G, Angelino NJ. Hydrolysis of aspirin by rat small intestine. J Pharm Sci. 1968; 57: 1449-50
• 24 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10: 1093-5
• 25 Schepp W. Proton pump inhibitory therapy: then and now. Yale J Biol Med. 2007; 69: 175-86
• 26 Peres O, Oliveira CH, Barrientos-Astigarraga RE, Rezende VM, Mendes GD, de Nucci G. Determination of pantoprazole in human plasma by LC-MS-MS using lansoprazole as internal standard. Arzneimittelforschung. 2004; 54: 314-9